首页>投融资
Alentis Therapeutics
D轮
Alentis Therapeutics AG discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC). The company was founded in 2019.Alentis Therapeutics AG is headquartered in Switzerland and its R&D department is in Strasbourg, France.In April 2023, Alentis Therapeutics AG raised US$105 million in Series C financing,.In June 2021, Alentis Therapeutics AG raised USD67 million in a Series B funding round.In April 2019, the company raised CHF 12.5 million (EUR 11.1 million; US $12.5 million) in a series A financing round
基本信息
-
公司全称Alentis Therapeutics AG
-
类型单抗药物研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址Gewerbestrasse 24 ALLSCHWIL BASEL-LANDSCHAFT 4123; CH;
-
联系电话49 157 58779471
-
邮箱info@alentis.ch
-
成立时间2019-03-01
投融资
-
2024-11-12D轮1.81亿美元奥博资本诺和诺德Jeito CapitalFrazier ManagementLongitude CapitalCatalio Capital ManagementAvego Bioscience CapitalRA Capital五源资本Bpifrance
-
2023-04-13C轮1.05亿美元Schroders CapitalJeito CapitalBpifrancePureos BioventuresRA CapitalNovo Holdings
-
2023-04-13C轮1.05亿美元RA CapitalPureos BioventuresJeito Capital诺和诺德Schroders CapitalBpifrance
-
2021-06-15B轮6700万美元Schroders CapitalHigh-TechGründerfonds五源资本BioMedPartnersJeito CapitalBpifrancePureos Bioventures
-
2021-06-15B轮6700万美元五源资本Schroders CapitalHigh-TechGründerfondsBpifrancePureos BioventuresBioMedPartnersJeito Capital
-
2019-04-30A轮1250万瑞士法郎High-TechGründerfondsBioMedPartnersBpifrancePureos BioventuresSchroder Adveq
-
2019-04-30A轮1250万瑞士法郎Schroder AdveqPureos BioventuresBioMedPartnersHigh-TechGründerfondsBpifrance
- 加载更多
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息